Certain gene mutations can dramatically increase the risk of developing aggressive prostate cancer. That's why Johnson & Johnson is researching a new way to fight the disease—one that involves blocking cancer cells from repairing their own damaged DNA.
Harnessing the immune system to target cancer is the goal of a groundbreaking area of oncology research called cell therapy. And Johnson & Johnson is hard at work in the cutting-edge field, aiming to deliver potential newtreatment options to people around the world.
Imagine living with a genetic disease that could cause blindness in your 40s—and your doctor tells you there are no treatment options. It's for patients like these that Johnson & Johnson is harnessing cutting-edge technology in the hope of finding real solutions.
The company honored him in 2013 with a Dr. Paul Janssen Award for Biomedical Research; now he's a Nobel Laureate. Learn about the transformational research that's led to these well-deserved scientific accolades.
The company is calling for ideas from applicants in Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia with the aim of helping to address racial healthcare disparities at the local level.
From backing an app that connects Black women to caregivers of color to developing a digital platform that supports surgical recovery, Johnson & Johnson is helping drive the surge of innovation in telemedicine.
Normally, in this part of Uganda, medication is delivered by boat—a slow, difficult process. But now a new Johnson & Johnson-supported program is using drones that can serve 20 landing sites across five islands, reaching more than 3,700 people in a single day.
Johnson & Johnson's 2020 Health for Humanity Report details the progress it's made in the past five years in driving sustainable social, environmental and economic change around the globe. Now the company's looking ahead to the next five.